Literature DB >> 20434974

Estimating key parameters in periodic breast cancer screening-application to the Canadian National Breast Screening Study data.

Yinlu Chen1, Guy Brock, Dongfeng Wu.   

Abstract

PROBLEM STATEMENT: Breast cancer screening in women of younger age has been controversial. The screening sensitivities, transition probabilities and sojourn time distributions are estimated for females aged 40-49 years and 50-59 years separately, using the Canadian National Breast Screening Study (CNBSS) data. The purpose is to estimate the lead time distribution and the probability of not detecting the cancer early. APPROACH: Within the 40-49-year-old and 50-59-year-old cohorts separately, the age-independent statistical model was applied. Bayesian estimators along with 95% highest probability density (HPD) credible intervals (CI) were calculated. Bayesian hypothesis testing was used to compare the parameter estimates of the two cohorts. The lead time density was also estimated for both the 40-49 and 50-59-year-old cohorts.
RESULTS: The screening sensitivity, transition probability of the disease, and mean sojourn time were all found to increase with age. For the 40-49-year-old and 50-59-year-old cohorts, the posterior mean sensitivities were 0.70 (95% HPD-CI: 0.46, 0.93) and 0.77 (0.61, 0.93), respectively. The posterior mean transition probabilities were 0.0023 (0.0018, 0.0027) and 0.0031 (0.0024, 0.0038), while the posterior mean sojourn times were 2.55 (1.56, 4.26) years and 3.15 (2.12, 4.96) years. Bayes factors for the ratio of posterior probabilities that the respective parameter was larger vs. smaller in the 50-59-year-old cohort were estimated to be 2.09, 40.8 and 3.0 for the sensitivity, transition probability, and mean sojourn time, respectively. All three Bayes factors were larger than two, indicating greater than 2:1 odds in favor of the hypothesis that each of these parameters was greater in the 50-59-year-old cohort. The estimated mean lead times were 0.83 years and 0.96 years if the two cohorts were screened annually.
CONCLUSIONS: The increase in sensitivity corresponds to an increase in the mean sojourn time. Breast cancer in younger women is more difficult to detect by screening tests and is more aggressive than breast cancer in older women. Women aged 50-59 tend to benefit more from screening compared with women aged 40-49.

Entities:  

Mesh:

Year:  2010        PMID: 20434974      PMCID: PMC2910214          DOI: 10.1016/j.canep.2010.04.001

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  12 in total

1.  Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations.

Authors:  Y Shen; M Zelen
Journal:  J Clin Oncol       Date:  2001-08-01       Impact factor: 44.544

2.  MLE and Bayesian inference of age-dependent sensitivity and transition probability in periodic screening.

Authors:  Dongfeng Wu; Gary L Rosner; Lyle Broemeling
Journal:  Biometrics       Date:  2005-12       Impact factor: 2.571

3.  Estimating mean sojourn time and screening test sensitivity in breast cancer mammography screening: new results.

Authors:  Harald Weedon-Fekjaer; Lars J Vatten; Odd O Aalen; Bo Lindqvist; Steinar Tretli
Journal:  J Med Screen       Date:  2005       Impact factor: 2.136

4.  Sojourn time, sensitivity and positive predictive value of mammography screening for breast cancer in women aged 40-49.

Authors:  S W Duffy; H H Chen; L Tabar; G Fagerberg; E Paci
Journal:  Int J Epidemiol       Date:  1996-12       Impact factor: 7.196

5.  Some pitfalls in the evaluation of screening programs.

Authors:  M Feinleib; M Zelen
Journal:  Arch Environ Health       Date:  1969-09

6.  Age specific sensitivity and sojourn time in a breast cancer screening programme (DOM) in The Netherlands: a comparison of different methods.

Authors:  C T Brekelmans; P Westers; J A Faber; P H Peeters; H J Collette
Journal:  J Epidemiol Community Health       Date:  1996-02       Impact factor: 3.710

7.  Bayesian inference for the lead time in periodic cancer screening.

Authors:  Dongfeng Wu; Gary L Rosner; Lyle D Broemeling
Journal:  Biometrics       Date:  2007-09       Impact factor: 2.571

8.  Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years.

Authors:  A B Miller; C J Baines; T To; C Wall
Journal:  CMAJ       Date:  1992-11-15       Impact factor: 8.262

9.  Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years.

Authors:  A B Miller; C J Baines; T To; C Wall
Journal:  CMAJ       Date:  1992-11-15       Impact factor: 8.262

10.  Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial.

Authors:  L Tabar; G Fagerberg; H H Chen; S W Duffy; C R Smart; A Gad; R A Smith
Journal:  Cancer       Date:  1995-05-15       Impact factor: 6.860

View more
  5 in total

1.  How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening.

Authors:  Elisabeth M Wever; Gerrit Draisma; Eveline A M Heijnsdijk; Harry J de Koning
Journal:  Med Decis Making       Date:  2011-03-15       Impact factor: 2.583

2.  Inference of Onset Age of Preclinical State and Sojourn Time for Breast Cancer.

Authors:  Dongfeng Wu; Seongho Kim
Journal:  Med Res Arch       Date:  2022-02

3.  Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis.

Authors:  Ayush Sharma; Thomas C Smyrk; Michael J Levy; Mark A Topazian; Suresh T Chari
Journal:  Gastroenterology       Date:  2018-04-30       Impact factor: 22.682

4.  Parameter estimates for invasive breast cancer progression in the Canadian National Breast Screening Study.

Authors:  S Taghipour; D Banjevic; A B Miller; N Montgomery; A K S Jardine; B J Harvey
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

5.  Inferences for the Lead Time in Breast Cancer Screening Trials under a Stable Disease Model.

Authors:  Justin Shows; Dongfeng Wu
Journal:  Cancers (Basel)       Date:  2011-04-26       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.